New England Journal of Medicine· 2017Q1· Clinical trial

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

Bruce Neal, Vlado Perkovic, Kenneth W. Mahaffey, Dick de Zeeuw et al.

7,801citations
Q1SCImago
2017year

Short summary

In patients with type 2 diabetes and high cardiovascular risk, canagliflozin significantly reduced major cardiovascular events by 14% compared to placebo over nearly 4 years.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Endocrinology, Diabetes and Metabolism

Endocrinology, Diabetes and MetabolismMedicine